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Functionalized MCM-48 as 
Carrier for In Vitro Controlled 
Release of an Active Biomolecule, 
L-Arginine
Anjali Uday Patel and Priyanka Dipakbhai Solanki
Abstract
The present chapter describes the synthesis, characterizations, and applica-
tion of MCM-48 functionalized by an inorganic moiety, as a carrier. MCM-48 
functionalized by 12-tungstophophoric acid (TPA) (TPA-MCM-48) and L-arginine 
was loaded into pure as well as functionalized MCM-48. Both the materials were 
characterized by various physicochemical techniques and evaluated for in vitro 
release of L-arginine at body temperature under different conditions. A study on 
release kinetics was carried out using first-order release kinetic model, while the 
mechanism were by Higuchi model. Further, to see the influence of TPA on release 
rate, release profile obtained from pure and functionalized MCM-48 was compared.
Keywords: MCM-48, 12-tungstophosphoric acid, L-arginine, in vitro release, 
kinetics and mechanism
1. Introduction
A semi essential amino acid, L-arginine is the main source of generation of 
NO via NO synthase (NOS), nitric oxide (NO), polyamines and agmatine, which 
also influence hormonal release and the synthesis of pyrimidine bases [1–4]. The 
three NOS isoforms have been found to be expressed in the kidney [4]. In the 
kidney endothelial NOS is important in the maintenance of glomerular filtration 
rate, regional vascular tone, and renal blood flow. The neuronal NOS (nNOS) 
is expressed primarily in the macula densa and participates in the control of 
glomerular hemodynamic via tubuloglomerular feedback and rennin release. The 
inducible (iNOS) is expressed in the kidney under pathological condition in the 
glomerular mesangium, infiltrating macrophages and tubules [5]. L-arginine is 
the substrate for arginases, a group of enzyme that are involved in tissue repair 
processes and that metabolize L-arginine to l-ornithine [6] as well as precursor 
for polyamine synthesis which is also involved in tissue repair and wound heal-
ing [7, 8]. During the time of stress, body does not provide sufficient amount of 
L-arginine for metabolic needs. Hence, under this condition, L-arginine supple-
mentation has been considered as an adjunct treatment for restoring normal func-
tion [7, 9, 10]. It was also found that compared to oral administration, intravenous 
administration of L-arginine to the patients with coronary artery disease increases 
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the bioavailability of vascular nitric oxide (NO) which shows the vasodilator 
effect. Further, it was found that in case of oral administration, the bio-availability 
of L-arginine decreases as it is utilized by arginase for the production of urea and 
ornithine and thus competes with NO synthase for substrate availability [1, 11], 
40% L-arginine is degraded in the intestine by arginase [12]. The mentioned prob-
lem can be overcome if some carrier will be used. The advantage of using carrier 
is expected to provide sufficient amount of L-arginine for NO production as the 
carrier can effectively load the desired amount of L-arginine as well as release it in 
control manner.
Thus, even though, L-arginine is important and is used as drug under certain 
conditions, no work has been found on controlled release of L-arginine except one 
which deals with the adsorption of L-arginine on SBA-15 at different pH by Deng 
et al. [13].
As M41S family have properties like higher surface area, ordered porosity, 
higher adsorption capacity, biocompatibility and non-cytotoxicity, they have 
been effectively explored as drug delivery carrier [14] and a number of reports are 
available on unfunctionalized or functionalized MCM-41/SBA-15 [15–40]. At the 
same time, very few reports are available on MCM-48, another important member 
of the M41S family as drug delivery carrier [40–43]. Arruebo et al. have reported 
iron loaded MCM-48 as drug delivery carrier [40]. Yang et al. have reported 
functionalization of MCM-48 by hydroxyapatite and used as a carrier for captopril 
[41]. Gai et al. have reported in vitro release of captopril using MCM-48 functional-
ized by VO4:Eu3+ [42]. Aghaei et al. have reported in vitro release of ibuprofen 
using MCM-48 functionalized by hydroxyapatite [43]. Recently, Popat et al. have 
reported the release profile of Sulfasalazine from MCM-48. [44]. Choi et al. have 
reported the comparative study for release of hydrophilic dye (Rose bengal) and 
hydrophobic molecule [Camptothecin (CPT) and Rhodamine 6G (R6G)] from 
MCM-48 [45]. Berger et al. have reported comparative study for release of amino-
glycoside from MCM-48 [39].
A literature survey shows that MCM-48 has been used as a carrier either in pure 
form or in functionalized form using organic moiety [41, 44, 46] and no reports are 
available on functionalization of MCM−48 by inorganic moiety.
In this regard, polyoxometalates (POMs), early transition metal oxygen anion 
clusters with metal in their higher oxidation states, are excellent candidates for the 
same as they have already been used in medicinal chemistry. The most investigated 
POMs are the Keggin type, represented by the general formula [Xnn+M12O40](8-n)-, 
where Xnn+ is a central heteroatom (Si4+, P5+, etc.) and M is an addenda atom (W6+, 
Mo6+, V5+, etc.). They have large number of water molecules and terminal oxygen 
atoms through which they can bind to the different functional groups of drug 
molecules. Literature survey shows that amongst all Keggin POMs, 12-tungsto-
phosphoric acid (TPA) has been widely used in medicinal chemistry [47–51]. In the 
present chapter, first time we are describing the use of 12-tungstophosphoric acid 
(TPA) for functionalization of MCM-48.
The present chapter describes synthesis of MCM-48, its functionalization by 
TPA (TPA-MCM-48) and encapsulation of L-arginine into TPA-MCM-48 (L-arg1/
TPA-MCM-48) as well as their characterization using various physicochemical 
techniques. In vitro release of L-arginine was carried out at body temperature under 
static and dynamic condition and different pH. L-arginine release kinetics and 
mechanism was also investigated using first order release kinetic model and Higuchi 
model. Further, in order to see the influence of TPA on release rate, L-arginine was 
loaded on pure MCM-48 (L-arg1/MCM-48) and its release study was carried out 
under same experimental condition.
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2. Experimental
2.1 Materials
L-arginine (SRL), Tetraethyl Orthosilicate (TEOS), Cetyltrimethylammonum 
Bromide (CTAB), Ninhydrin, Sodium hydroxide (NaOH), 12-Tungstophosphoric 
acid (TPA) and Ethanol (absolute) were received from Merck. All the chemicals 
were of A.R. Grade and used without any further purification.
Simulated body fluid (SBF): NaCl (7.996 g), NaHCO3 (0.350 g), KCl (0.224 g), 
K2HPO4.3H2O (0.22 g), MgCl2.6H2O (0.305 g), 1 molL
−1 HCl (40 ml), CaCl2 
(0.278 g), Na2SO4 (0.071 g) and NH2C(CH2OH)3 (6.057 g) were dissolved in small 
amount of water and then dilute to 1 L with distilled water [46, 52].
Simulated gastric fluid (SGF): 6.217 g of conc. HCl was place into 1 L volumetric 
flask and then diluted up to the mark using distilled water.
2.2 Synthesis of mesoporous MCM-48
The synthesis of MCM-48 was carried out as described in literature [53]. 2.4 g of 
CTAB was dissolved in 50 ml distilled water. To this clear solution of CTAB, 50 ml 
ethanol (0.87 mole) and 12.6 ml ammonia (32 wt%, 0.20 mole) were added. The 
mixture was then stirred for 10 min. After 10 min, 3.4 g TEOS (16 mole, 3.6 mL) 
was added to this homogeneous solution. The mixture was then stirred for 2 h. 
After stirring, the resulting white solid was filtered and wash with distilled water. 
The dried white material then calcined at 823 K for 6 h to remove the template. The 
resulting material was designated as MCM-48.
2.3 Synthesis of TPA functionalized MCM-48 (TPA-MCM-48)
MCM-48 was functionalized using TPA as functionalizing agent by incipient 
wet impregnation method [54]. 30% of TPA anchored to MCM-48 was synthesized. 
One g of MCM-48 was impregnated with an aqueous solution of TPA (0.3/30 g/mL 
of distilled water) and dried at 100°C for 10 h. The obtained material was desig-
nated as TPA-MCM-48.
2.4 Loading of L-arginine on TPA-MCM-48 and MCM-48
Loading of L-arginine was also carried out by incipient wet impregnation 
method where 1 g of TPA-MCM-48 and MCM-48 were impregnated with an aque-
ous solution of L-arginine (0.1 g/10 mL) and pH of the mixture was adjusted up to 
4 using 0.1 M HCl solution and mixture was dried at 100°C for 5 h. The obtained 
material was designated as L-arg1/TPA-MCM-48. Loading amount was also con-
firmed by thermal analysis which shows 0.1 g of L-arginine was loaded per g of 
both materials (TPA-MCM-48 and MCM-48). All the experiments were carried out 
three times for finding % errors with in data.
2.5 Preparation of calibration curve for determination of L-arginine
To obtained calibration curve of L-arginine, stock solution was prepared by dis-
solving 1 g of it in 100 ml SBF (1 mg/mL). Series of 25 mL Nessler’s tubes contain-
ing 0.15–0.4 mL of this stock solution was diluted up to the 4 mL using distilled 
water. 1 mL of acetate buffer (pH 5.5) and 1 mL ninhydrin reagent (10% ninhydrin 
solution in ethanol) were added to diluted solutions. All the tubes were placed in 
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boiling water bath up to 15 min for completion of reaction which was seen by the 
formation of purple color. The solutions were cooled under tap water, followed 
by addition of 1 mL of 50% ethanol and absorption was taken at 570 nm using 
Systronics UV–Visible-spectrophotometer. Similarly, calibration curve was obtained 
in SGF (Figure 1).
2.6 Characterization
The FTIR spectra of all materials were obtained by using KBr palate on Perkin 
Elmer instrument. TGA of the materials were carried out using a Mettler Toledo 
Star SW 7.01 instrument under nitrogen atmosphere from 30 to 570°C at the heat-
ing rate of 10°C/min. Adsorption–desorption isotherms of MCM-48, TPA-MCM-48 
and L-arg1/TPA-MCM-48 were recorded on a Micromeritics ASAP 2010 Surface 
area analyzer at liquid nitrogen temperature. From the adsorption desorption 
isotherms, specific surface area was calculated using BET method. The XRD pattern 
was obtained on PHILIPS PW-1830, with Cu Kα radiation (1.54 Å) and scanning 
angle from 0° to 10°. TEM analysis was carried out on JEOL (JAPAN) TEM instru-
ment (model-JEM 100CX II) with accelerating voltage of 200 kV. The samples were 
dispersed in ethanol and ultrasonicated for 5–10 min. A small drop of the sample 
was then taken in a carbon coated copper grid and dried before viewing. 31P MAS 
NMR spectra were recorded by BRUKER Avance DSX-300, at 121.49 MHz using a 
7 mm rotor probe with 85% phosphoric acid as an external standard. The spinning 
rate was 5–7 kHz. Catalyst samples, after treatment were kept in a desiccator over 
P2O5 until the NMR measurement. The 
29Si NMR spectra were recorded at Mercury 
Plus 300 MHz using a 5 mm Dual Broad Band rotor probe with TMS as an external 
standard.
2.7 In vitro release study of L-arginine
In vitro release profile of L-arginine was obtained by soaking 0.5 g of L-arginine 
loaded materials in 62.5 mL of SBF (0.8 mg of L-arginine in 1 mL SBF) at tempera-
ture of 37°C with 200 rpm. At predetermined time interval, 0.5 mL of released fluid 
was taken and immediately equal amount of fresh SBF was added to maintain the 
constant volume. This release fluid was analyzed for L-arginine content by treat-
ing it with 10% ninhydrin solution at 570 nm using UV–Visible spectrophotometer 
(PerkinElmer). Same study was also carried under static condition as well as at 
different pH (pH 7.4 and pH 1.2). All the experiments were repeated three times.
Figure 1. 
Calibration curve of L-arginine in (A) SBF and (B) SGF.
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3. Result and discussion
3.1 Material characterization
FTIR spectrum of MCM-48 shows a broad band around 1100 and 1165 cm−1 
corresponding to asymmetric stretching of Si-O-Si (Figure 2b), the bands at 640 
and 3448 cm−1 are corresponding to symmetric vibrations of Si-O-Si and stretching 
vibration Si-OH band, respectively, in good agreement with the reported one [55]. 
The presence of typical bands of TPA at 982 cm−1 corresponding to Vas vibration 
of W = Od, and 897 cm
−1 for stretching vibrations of W-O-W, in TPA-MCM-48 [56] 
suggest the primary structure of TPA is remain intact even after functionalization 
of MCM-48. The absence of vibration band at 1080 cm−1 (Vs stretching of P-O) of 
TPA may be due to superimposition on the bands of MCM-48. The FTIR spectrum 
of L-arginine shows bands around 3151, 1680, 1574 cm−1 corresponds to N–H 
stretching vibration, NH2 in plan bending vibration and C=O stretching vibration 
[57]. FTIR spectrum of L-arg1/TPA-MCM-48 (Figure 2d) shows entire bands cor-
responding to TPA-MCM-48 with lower intensity suggesting multiple adsorption of 
it into TPA-MCM-48 which is further confirmed by Nitrogen adsorption–desorp-
tion surface area analysis (Figure 3 and Table 1). It shows some additional bands 
at 3183 cm−1 due to the N-H stretching, 1690 cm−1 due to NH2 in plane bending 
vibration and 1552 cm−1 due to C=O stretching vibration. The observed Shifting 
in the bands correspond to C=O group and N-H group indicate the interaction of 
L-arginine to TPA-MCM-48 through these functional group.
TGA analysis of pure MCM-48, TPA-MCM-48 and L-arg1/TPA-MCM-48 are 
shown in Figure 3. MCM-48 shows initial weight loss of 0.7% up to 100°C. This 
initial weight loss may be due to adsorption of physically adsorbed water molecules. 
After that, no further weight loss is observed.
TGA curve of TPA-MCM-48 shows initial weight loss of 10–13% up to 100°C 
which indicate presence of adsorbed water, while the Second weight loss of 1–2% 
between 200 and 300°C corresponds to the loss of water of crystallization of Keggin 
Figure 2. 
FTIR spectra of (a) TPA, (b) MCM-48, (c) TPA-MCM-48 and (d) L-arg1/TPA-MCM-48.
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ion. A gradual weight loss from 300 to 500°C was observed due to the difficulty in 
removal of water present in TPA molecules inside the channels of MCM-48. This 
types of inclusion can cause the stabilization of TPA molecules inside the channels 
of MCM-48.
TGA curve of L-arg1/TPA-MCM-48 shows initial weight loss of 2.45% up to 
100°C and further weight loss of 9.93% from 200 to 500°C. Initial weight loss may 
be due to the presence of adsorbed water. Weight loss from 200 to 490°C may be 
because of the removal of L-arginine from TPA-MCM-48.
Figure 3 shows nitrogen adsorption–desorption isotherm of MCM-48, TPA-
MCM-48 and L-arg1/TPA-MCM-48 and textural parameters are shown in Table 1. 
Isotherms of MCM-48 is type IV in nature and according to IUPAC classification it 
is the characteristic of mesoporous solids. This also suggests that functionalization 
as well as loading of L-arginine does not alter the structure of MCM-48 Decrease 
in surface area and pore volume is observed after functionalization of MCM-48 
by TPA suggests the strong interaction of TPA with MCM-48. Further decrease 
in surface area and pore volume is observed in case of L-arg1/TPA-MCM-48 
which suggests the encapsulation of L-arginine into the mesoporous channel of 
TPA-MCM-48.
Figure 5 shows Low angle powder XRD of MCM-48, TPA-MCM-48 and L-arg1/
TPA-MCM-48. The XRD pattern of MCM-48 shows main characteristic peaks at 
2.3° which indicates the presence of intact structure of MCM-48. It also shows broad 
shoulder at 3.0° corresponding to a plane 211 and 220, respectively. Several peaks 
in the range of 4–5° diffraction angles correspond to the reflections of 400, 321 and 
420 planes of a typical MCM-48 meso-structure with Ia3d cubic symmetry. It is 
well known that the low angle XRD pattern are sensitive to pore filling and loaded 
materials show lowered intensity of characteristic peak compared to pure one. XRD 
Figure 3. 
TGA analysis (a) MCM-48, (b) TPA-MCM-48 and L-arg1/TPA-MCM-48.
Materials Specific surface area (m2/g) Pore volume (cm3/g)
MCM-48 1141 0.67
TPA-MCM-48 566 0.22 [R,S]
L-arg1/TPA-MCM-48 68 0.10
L-arg1/MCM-48 109 0.25
Table 1. 
Textural properties of MCM-48, TPA-MCM-48, L-arg1/TPA-MCM-48 and L-arg1/MCM-48.
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pattern of TPA-MCM-48 and L-arg1/TPA-MCM-48 shows characteristics peak at 
2θ = 2.3° with lower intensity. Absence of any other peak indicates the insertion as 
well as homogeneous distribution of L-arginine into the mesoporous channels of 
TPA-MCM-48. In addition to this, disappearance of secondary peak at 2θ = 3–5° 
in case of L-arg1/TPA-MCM-48 was observed. This is because further loading of 
L-arginine into functionalized MCM-48 may block the channels which have already 
been confirmed by BET analysis.
Figure 6 shows TEM images of MCM-48, TPA-MCM-48 and L-arg1/TPA-
MCM-48 at 50 nm resolution. The TEM image of MCM-48 shows very well ordered 
pore system with spherical morphology. It is well known in literature, that MCM-48 
has a three dimensional pore system with two non-intersecting gyroidal pores. 
The TEM image of TPA-MCM-48 shows similar spherical morphology with porous 
system suggesting intact structure of MCM-48 even after functionalization. The 
TEM images of L-arg1/TPA-MCM-48 also show spherical morphology and porous 
structure. Absence of any aggregation in TEM images of L-arg1/TPA-MCM-48 
suggests the homogeneous dispersion of L-arginine on TPA-MCM-48. Further the 
structure of TPA-MCM-48 remains intact even after loading of L-arginine.
Figure 5. 
Low angle powder XRD of (A) MCM-48, (B) TPA-MCM-48 and (C) L-arg1/TPA-MCM-48.
Figure 4. 
Nitrogen adsorption–desorption isotherms of (a) MCM-48, (b) TPA-MCM-48 and (c) L-arg1/
TPA-MCM-48.
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31P MAS NMR is the most important method to study chemical environment 
around the phosphorous in heteropoly compounds. The 31P MAS NMR spectra 
of TPA-MCM-48 and L-arg1/TPA-MCM-48 are shown in Figure 7. The pure TPA 
shows single peak at −15.62 ppm and is in good agreement with the reported one 
[58]. The 31P MAS NMR spectra of TPA-MCM-48 shows two peak at −12.27 and 
3.060 ppm. The observed shift from −15.62 to −12.27 ppm is attributed to the 
strong interaction of MCM-48 with that of TPA as well as the presence of TPA 
inside the MCM-48. These results are in good agreement with reported one [59].
Further shift in this peak is observed from −12.27 to −9.24 ppm for L-arg1/TPA-
MCM-48 which also suggest the interaction of TPA with that of L-arginine which 
was further confirmed by 29Si MAS NMR.
29Si MAS NMR is a useful technique to study the chemical environment around 
the silicon nuclei in the mesoporous materials. Figure 8 represents the 29Si MAS 
NMR spectra of MCM-48, TPA-MCM-48 and L-arg1/TPA-MCM-48. A broad peak 
of MCM-48 between −90 to −125 ppm observed which can be attributed to three 
main part of the peak with chemical shift at −92, −99 and − 108 ppm (Figure 8a, 
Table 2). These signals resulted from Q2 (−92 ppm), Q3 (−99 ppm) and Q4 
(−108 ppm) silicon nuclei.
Figure 6. 
TEM images of MCM-48, TPA-MCM-48 and L-arg1/TPA-MCM-48 at 200, 100 and 50 nm resolution.
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All the three, Q2, Q3 and Q4 bands are observed in NMR spectra of TPA-
MCM-48 (Figure 8b) suggesting the intact structure of MCM-48 even after 
functionalization. However, significant shift is observed in Q2 band from −92 to 
−88 (Table 2) suggests the interaction of Si-OH group of MCM-48 with TPA.
The 29Si MAS NMR spectra of L-arg1/TPA-MCM-48 show characteristic peaks 
(Figure 8c) of TPA-MCM-48 (Table 2). No significant shift in the Q2, Q3 and Q4 
bands suggests that the structure of TPA-MCM-48 remains intact even after loading 
of L-arginine. This further confirms that the L-arginine molecules selectively bind 
with TPA and not to the surface Si-OH group of MCM-48.
Figure 7. 
31P MAS NMR of (a) TPA-MCM-48 and (b) L-arg1/TPA-MCM-48.
Figure 8. 
(a) MCM-48, (b) TPA/MCM-48 and (c) L-arg1/TPA-MCM-48.
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3.2 In vitro release study of L-arginine
3.2.1 Effect of stirring on release rate of L-arginine
In vitro release profile of L-arg1/TPA-MCM-48 in SBF under static and stirring 
condition at 37°C was carried out and results are shown in Figure 9. Initially 28% 
of L-arginine is released under both the condition but after that more slower and 
delayed release is observed in case of static condition. It reached to 51 and 38% up 
to 10 h and 86 and 46% up to 32 h under stirring and static condition respectively. 
The slower release of L-arginine is may be due to the slow diffusion of L-arginine 
molecules under static condition.
As stated earlier all the experiments were carried out thrice. Statistics tool 
ANOVA was applied and the experimental errors within the data was found to 
be ±2%. The results of ANOVA single factor for release of L-arginine from TPA-
MCM-48 under stirring and static condition are shown in Table 3. The calculated F 
values (0.339 under stirring and 3.062 under static conditions) are less than tabu-
lated F value (3.09 under stirring and 3.097 under static conditions), and statisti-
cally significant difference (P) of 0.713 and 0.051 were obtained under stirring and 
static conditions respectively.
3.2.2 Effect of pH on release rate of L-arginine
To see the effect of pH on release rate of L-arginine, release study was carried 
out into SBF (pH 7.4) and SGF (pH 1.2) and results are compared (Figure 10). 
Figure 10. Shows slower release rate of L-arginine at lower pH. It is known that 
Figure 9. 
In vitro release profile of L-arginine under (a) stirring condition and (b) static condition.
Sr. No. Materials 29Si MAS NMR data
Q2 ppm Q3 ppm Q4 ppm
1. MCM-48 −92 −99 −108
2. TPA-MCM-48 −88 −98 −108
3. L-arg1/TPA-MCM-48 −87 −98 −108
Table 2. 
29Si chemical shift of MCM-48, TPA-MCM-48 and L-arg1/TPA-MCM-48.
11
Functionalized MCM-48 as Carrier for In Vitro Controlled Release of an Active Biomolecule…
DOI: http://dx.doi.org/10.5772/intechopen.90175
L-arginine acquires two positive charges at pH 1.2 becomes Arg2+ [60] which may 
have strong interaction with TPA-MCM-48. While at pH 7.4 it remain as Arg+ which 
may have comparatively weaker interaction with TPA-MCM-48 which allows easy 
diffusion of L-arginine at pH 7.4.
Under similar lines, ANOVA has also been applied for L-arginine release at 
different pH, and experimental error of ±2% within the data was obtained. From 
the results presented in Table 4, it can be seen that the calculated F values (0.339 
Condition Source of variation SS df MS F P-value F crit
Stirring Between groups 248 2 124 0.339 0.713 3.097
Within groups 32878.21 90 365.31
Total 33126.21 92
Static Between groups 248 2 124 3.062 0.051 3.097
Within groups 3644.169 90 40.49
Total 3892.169 92
SS: sum of squares; Df: degree of freedom; MS: mean squares.
Table 3. 
Results of ANOVA single factor.
Figure 10. 
In vitro release profile of L-arg1/TPA-MCM-48 in SBF (pH 7.4) and in SGF (pH 1.2).
Condition Source of 
variation
SS df MS F P-value F crit
In SBF (pH 7.4) Between groups 248 2 124 0.339 0.713 3.097
Within groups 32878.22 90 365.3136
Total 33126.22 92
In SGF (pH 1.2) Between groups 240.086 2 120.043 0.41457 0.661879 3.098
Within groups 26060.44 90 289.5605
Total 26300.53 92
SS: sum of squares; Df: degree of freedom; MS: mean squares.
Table 4. 
Results of ANOVA single factor.
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at pH 7.4 and 0.414 at pH 1.2) are less than tabulated F value (3.09 at pH 7.4 and 
pH 1.2), and statistically significant difference (P) of 0.713 and 0.661 were obtained 
at pH 7.4 and 1.2 respectively.
3.2.3 Release kinetic and mechanism
For finding the drug release kinetic and mechanism released data up to 10 h were 
fitted with first order release kinetic model, Higuchi model and results are shown in 
Figure 11 [61–63].
First order release kinetic model used to study the kinetic of release of soluble 
drugs. According to this model release of drug is concentration dependent process. 
Figure 11A shows first order release kinetic model of L-arg1/TPA-MCM-48. The 
release of L-arginine follows the first order release kinetic model with higher linear-
ity and co-relation coefficient (R2 = 0.983).
Figure 11B Shows Higuchi model of L-arg1/TPA-MCM-48 where % release 
of L-arginine was plotted against square root of time based on Fickian diffusion 
mechanism. According to this model release mechanism involves simultaneous pen-
etration of SBF into the pores of carriers, dissolution of drug molecules and diffu-
sion of these molecules from the carriers. This release data up to 10 h was best fitted 
with Higuchi model with higher linearity and co-relation coefficient (R2 = 0.9863) 
and follows Fickian diffusion mechanism.
Hence release profile of L-arginine follows first order release kinetic model as 
well as Higuchi model.
3.2.4  Comparison of release profile of L-arginine from MCM-48 and TPA-
MCM-48: role of TPA on release rate
To see the effect of TPA on release rate of L-arginine, release profile of L-arg1/
MCM-48 and L-arg1/TPA-MCM-48 has been compared and results are shown in 
Figure 12. It is clear from the Figure 12 that slower release profile is obtained for 
TPA-MCM-48 compared to pure MCM-48. In case of L-arg1/MCM-48, initially 62% 
of L-arginine was released and reached to 76% up to 10 h. while in case of L-arg1/
TPA-MCM-48, initially 28% L-arginine released and reached to 51% up to 10 h. 
Thus, more controlled and ordered release rate is observed with TPA-MCM-48 
systems compared to pure MCM-48. The slower release of L-arginine may be due to 
the strong interaction between L-arginine and terminal oxygen of TPA, which was 
already confirmed from FTIR spectra. Further, the pore volume of L-arg1/MCM-48 
is bigger than L-arg1/TPA-MCM-48 (Table 1). So there may be easy diffusion of 
L-arginine molecules from MCM-48 compared to TPA-MCM-48. Here, TPA act as 
functionalizing agent and can hold the L-arginine for longer period of time.
Figure 11. 
(A) First order release kinetic model and (B) Higuchi model of L-arg1/TPA-MCM-48.
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Under similar lines, ANOVA has also been applied for L-arginine release from 
MCM-48 as well as TPA-MCM-48, and experimental error of ±2% within the 
data was obtained. From the results presented in Table 5, it can be seen that the 
calculated F values (1.449 for L-arg1/MCM-48 and 0.339 for L-arg1/TPA-MCM-48) 
are lesser than tabulated F value (3.113 for L-arg/MCM-48 and 3.097 for L-arg/
TPA-MCM-48), and statistically significant difference (P) of 0.240 and 0.713 were 
obtained for L-arg/MCM-48 and L-arg/TPA-MCM-48 respectively.
Further, to see that TPA is actually acting as functionalizing agent or not, FTIR 
analysis of L-arg1/TPA-MCM-48 was carried out after release study and spectrum 
is shown in Figure 13. It shows that bands correspond to N-H stretching vibration 
Figure 12. 
Release profile of L-arg1/MCM-48 and L-arg1/TPA-MCM-48.
Materials Source of 
variation
SS df MS F P-value F crit
L-arg/MCM-48 Between groups 216 2 108 1.449 0.240 3.113
Within groups 5811.41 78 74.505
Total 6027.41 80
L-arg/TPA-MCM-48 Between groups 248 2 124 0.339 0.713 3.0976
Within groups 32878.22 90 365.3136
Total 33126.22 92
SS: sum of squares; Df: degree of freedom; MS: mean squares.
Table 5. 
Results of ANOVA single factor.
Figure 13. 
FTIR spectrum of L-arg1/TPA-MCM-48 after release study.
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and CH3 in plan bending vibration are disappeared. This may be due to the removal 
of L-arginine from TPA-MCM-48 during the release study. However the bands 
correspond to NH2 in plan bending vibration and C=O stretching vibration show 
slight shifting with lower intensity. This suggests that some amount of L-arginine 
was remaining inside the TPA-MCM-48. That was also confirm from release study 
as it shows that 86% L-arginine was release up to 32 h and then it became constant. 
Further, bands corresponding to TPA-MCM-48 are remaining as it is and confirm 
the intact structure of TPA-MCM-48.
4. Conclusion
In this chapter first time we are reporting functionalization of MCM-48 using 
TPA and its application as carrier for L-arginine. FTIR and NMR studies shows that 
L-arginine interact with TPA-MCM-48 through its N-H and C=O group. Further, 
BET and TEM analysis shows that structure of MCM-48 remain intact even after 
functionalization as well as L-arginine loading. In vitro release studies suggest 
that more controlled and delayed release was obtained with TPA-MCM-48 system. 
Presence of TPA, delayed the release rate of L-arginine and this being of great 
importance in the field of controlled drug delivery system. Further kinetics and 
mechanism study shows that release of L-arginine follows first order kinetics with 
Fickian diffusion mechanism.
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